BUSINESS SEGMENT AND INTERNATIONAL OPERATION INFORMATION

12 Months Ended

Dec. 31, 2025

Segment Reporting [Abstract]

BUSINESS SEGMENT AND INTERNATIONAL OPERATION INFORMATION

BUSINESS SEGMENT AND INTERNATIONAL OPERATION INFORMATION

We have four reportable business segments (Asia, Europe, North America and Latin America and Other) based primarily upon the geographic region where each segment operates, as well as the internal organization of our officers and their responsibilities. Each of the geographic segments operate under the Nature’s Sunshine Products and Synergy WorldWide® brands and sell similar products grouped into six principal categories: general health, immune, cardiovascular, digestive, personal care and weight management. The Latin America and Other segment includes our wholesale business in which we sell products to various locally-managed entities, independent of the Company, that we have granted distribution rights for the relevant market.

The Company's chief operating decision maker ("CODM") is our chief executive officer. The CODM assesses the performance of each segment using operating income. The CODM reviews the performance of each segment using monthly internal reports which provide variance analysis of actual results by segment compared to budget, forecast and prior year. The CODM uses this information when making decisions about the allocation of operating resources to each segment. The CODM does not evaluate reportable segments using asset or liability information.

Reportable business segment information for the years ended December 31, 2025 and 2024 is as follows (dollar amounts in thousands):

2025	Asia		Europe		North America		Latin America and Other		Total
Net sales	$	221,777	$	93,133	$	143,611	$	21,623	$	480,144
Cost of sales	48,484		27,524		48,528		7,884
Volume incentives	71,185		37,359		29,485		6,562
Selling, general and administrative (1)	61,944		20,203		34,736		5,949
Segment operating income	$	40,164	$	8,047	$	30,862	$	1,228	$	80,301
Unallocated corporate selling, general and administrative expense									(55,558)
Operating income									24,743
Interest and other income, net									645
Interest expense									(98)
Foreign exchange gains, net									4,522
Income from operations before provision for income taxes									$	29,812

2024	Asia		Europe		North America		Latin America and Other		Total
Net sales	$	207,794	$	84,837	$	138,849	$	22,884	$	454,364
Cost of sales	48,557		27,836		45,364		7,918
Volume incentives	69,685		33,758		29,773		7,374
Selling, general and administrative (1)	55,443		18,577		32,793		6,299
Segment operating income	$	34,109	$	4,666	$	30,919	$	1,293	$	70,987
Unallocated corporate selling, general and administrative expense									(50,892)
Operating income									20,095
Interest and other income, net									177
Interest expense									(146)
Foreign exchange losses, net									(1,700)
Income from operations before provision for income taxes									$	18,426

___________________________

(1) Service fees in China totaled $16.8 million and $14.5 million for the years ended December 31, 2025 and 2024, respectively. These service fees are included in selling, general and administrative expenses for our Asia segment.

The table below reflects sales based upon the sales location where they occurred. From an individual country/region perspective, the United States, Taiwan, Japan and South Korea comprise 10 percent or more of consolidated net sales for the years ended December 31, 2025 and 2024 as follows (dollar amounts in thousands):

Year Ended December 31,	2025		2024
Net sales:
United States	$	133,387	$	127,924
Taiwan	67,280		70,579
Japan	56,070		43,940
South Korea	50,842		51,362
Other	172,565		160,559
Total net sales	$	480,144	$	454,364

Net sales generated by each product line for the years ended December 31, 2025 and 2024 are as follows (dollar amounts in thousands):

2025	Asia		Europe		North America		Latin America and Other		Total
General health	$	83,632	$	39,794	$	62,226	$	6,470	$	192,122
Immune	14,438		9,148		15,385		1,847		40,818
Cardiovascular	54,555		10,805		14,661		1,614		81,635
Digestive	47,673		24,601		41,804		10,290		124,368
Personal care	10,074		5,813		6,474		906		23,267
Weight management	11,405		2,972		3,061		496		17,934
Total net sales by segment	$	221,777	$	93,133	$	143,611	$	21,623	$	480,144

2024	Asia		Europe		North America		Latin America and Other		Total
General health	$	81,313	$	36,631	$	59,520	$	6,418	$	183,882
Immune	12,052		8,454		15,802		2,416		38,724
Cardiovascular	56,266		9,265		14,443		1,726		81,700
Digestive	38,958		22,748		39,325		10,713		111,744
Personal care	5,032		5,397		6,241		1,133		17,803
Weight management	14,173		2,342		3,518		478		20,511
Total net sales by segment	$	207,794	$	84,837	$	138,849	$	22,884	$	454,364

Depreciation and amortization by reportable business segment for the years ended December 31, 2025 and 2024, are as follows (dollar amounts in thousands):

Year Ended December 31,	2025		2024
Depreciation and amortization:
Asia	$	1,896	$	1,876
Europe	99		93
North America	11,801		12,204
Latin America and Other	48		46
Total depreciation and amortization	$	13,844	$	14,219

From an individual country perspective, only the United States has material balances of consolidated property, plant and equipment as follows (dollar amounts in thousands):

As of December 31	2025		2024
Property, plant and equipment, net
United States	$	29,061	$	34,786
Other	3,854		4,799
Total property, plant and equipment, net	$	32,915	$	39,585